$$ Advanced Cell Technology $$

“We recognize the importance of transparency and the need to become current in our financial reporting and are working diligently with our auditors to achieve this,” said William Caldwell, CEO of Advanced Cell. “Filing the 10-Q’s for two quarters last year is the first step in the process that will hopefully lead to a listing on the Bulletin Board. We believe such a listing should increase interest among the investment community in the significant progress we have made in developing our scientific platform, and our IND filing later this year when we will seek approval to commence human clinical trials for our retinal pigment epithelium (RPE) technology.”

About Advanced Cell Technology, Inc.

Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the field of regenerative medicine. For more information, visit www.advancedcell.com.

Forward-Looking Statements

Statements in this news release regarding future ability to draw on the credit Facility, future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the Company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates,” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: the Company’s ability to meet all of the conditions to allow it to access the entire amount available under the credit Facility discussed in this press release, limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company’s periodic reports, including the report on Form 10-QSB for the quarter ended September 30, 2007. Forward-looking statements are based on the beliefs, opinions, and expectations of the company’s management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.

Forward-looking statements are based on the beliefs, opinions, and expectations of the company’s management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.



CEOcast, Inc. for Advanced Cell Technology
Dan Schustack, 212-732-4300




Source: Business Wire (May 11, 2009 - 10:43 AM EDT)

News by QuoteMedia

"We look forward to developing this technology to identify solutions for diseases of the eye, which represent a large unmet medical need in Korea," said Mr. Moon, Byung-Woo, the CEO for CHA Bio. "Through our work with ACT, we believe its technology platform holds great promise in the field of regenerative medicine. And furthermore, this technology is well positioned to be used in clinical trials in the near future."

"We are extremely pleased to have the opportunity to expand our relationship with CHA Bio," said William Caldwell, CEO of Advanced Cell. "We expect that our collaborative efforts will accelerate the technology of regenerative medicine therapies internationally. We anticipate providing significant benefits to both companies and those whose lives will be positively impacted as a result of the research and clinical therapies derived from our cooperative efforts."

The companies previously announced that they formed a joint venture called "Stem Cell & Regenerative Medicine International." The new company is located in Worcester, MA and focuses on the development of human blood cells. It is
majority owned by CHA Bio and benefits from ACT exclusively licensing all of its hemangioblast technology to the joint venture.

ACT is currently focused on using its proprietary technologies to generate stable cell lines including retinal pigment epithelium (RPE) cells for the treatment of diseases of the eye. For example, AMD is a disorder that affects the macula of the eye that causes decreased visual acuity and increasing loss of central vision. The prevalence of AMD begins to increase after the age of 50. Approximately 15% of people over 75 years of age have the condition.

ACT demonstrated the ability to rescue visual function in rats through implantation of RPE cells derived from human embryonic stem cells. In collaboration with Dr Raymond Lund, then at the Moran Eye Institute at the University of Utah and currently working at the Casey Eye Institute at the Oregon Health and Science University, the Company performed RPE cell transplantation into the sub-retinal space in the eyes of RCS rats that naturally become blind in several weeks due to RPE degeneration and photoreceptor death. In the experiments sponsored by the Company, the rats were injected with embryonic stem derived RPE cells into the sub-retinal space of the eye at 21 days after their birth — an age at which photoreceptor degeneration has not yet occurred. As control measures, some rats received injections of cell culture medium alone or were not injected at all.

Subsequently, tests for visual function were performed at 60 and 90 days after birth — times at which loss of photoreceptor cell has produced characteristic vision deficits. The results represented a major breakthrough. The injected RPE cells grew normally without forming teratomas (tumors). Soon, the rats were able to follow light with their eyes and attained approximately 70% of the spatial acuity of a normal, healthy rat. Necropsy revealed that the eyes had grown layers of the retinal cells. The experiment demonstrated that animals receiving the human embryonic stem cell-derived RPE cells performed significantly better than medium-only treated (50% improvement), or untreated (100% improvement) controls in visual performance. In addition, the human embryonic stem cell-derived RPE cells did not appear to cause any side effects in the animals. The research was published in Cloning and Stem Cells and was also referenced in Scientific American.

5.Actc hat die führende Technologie, um aus Embryos Stammzellen zu gewinnen, ohne die Emb. zu töten
6. Über 200 Patente und mit Dr. Lanza einen der bekanntesten Vertreter der Stammzellenforschung
7. Eine lächerliche Mktcap von 10,7 Mio $ Es ist selbst für Laien erkennbar, dass eine industrielle Revolution wieder am Horizont erscheint: Stammzellentherapien. Von künstlich gezüchteten Zähnen bis zum Ersatzteil Organ,Arm usw. für Soldaten, für das sich das Pentagon interessiert, ist alles möglich. Das gilt auch für den Kurs der Aktie. Da gibt es nur eines: Akkumilieren und Ruhe bewahren.


1. ACTC kann embryonale Stammzellen gewinnen, ohne !!! den dazugehörigen Embryo zu töten. Wichtig für die religiöse Recht in USA
2. Sie haben ein JV, das an der Kommerzialisierung zur Herstellung von Blutzellen arbeitet, das ihnen 2,5 Mio einbringt.
3. Obama hat Bushs Bann aufgehoben, weil er wie viele Wissenschaftler überzeugt ist, dass die Stammzellenforschung die nächste industrielle Revolution auslösen wird.
4. Die öffentliche Meinung in USA hat gedreht, seit nahezu jeden Tag vielversprechende Ergebnisse mit Stammzellen gemacht werden, die unser aller Leben bis hin zur Züchtung von funktionierenden Organen ändern wird. Auf embryonale Stems kann allerdings nicht verzichtet werden, da sie u.a. auch als Kontrolle für rückgeführte pluripotente Zellen gebraucht werden.
5.Big Pharma steht doch schon an der Seitenlinie, um sofort dann einzusteigen, sobald ihre MArke nicht beeinträchtigt wird.
6. ACTC wird von den Pinks wieder zur OTC zuürckkommen und in den Genuss von öffentlichen Mitteln kommen.